<DOC>
	<DOCNO>NCT00483093</DOCNO>
	<brief_summary>The main objective trial document safety combination ( escalation dose NGR-hTNF , 0.2 mcg/sqm 1.6 mcg/sqm , fix dose cisplatin , 80 mg/sqm ) . Safety establish clinical laboratory assessment accord National Cancer Institute Common Toxicity Criteria ( NCI-CTC ) .</brief_summary>
	<brief_title>Study NGR-hTNF Combination With Cisplatin Solid Tumor</brief_title>
	<detailed_description>This phase IB , open-label , non-randomized , dose-escalation study conduct sequential cohort patient . Three patient per cohort plan . Patients , advance metastatic solid tumor amenable standard therapy enrol .</detailed_description>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patients ≥18 year advance metastatic solid tumor amenable clinical improvement current standard treatment suitable treatment cisplatin Life expectancy 3 month ECOG Performance status 01 Absence condition hypervolemia consequence ( e.g . increase stroke volume , elevate blood pressure ) may represent risk patient Adequate baseline bone marrow , hepatic renal function , define follow : Neutrophils &gt; 1.5 x 10^9/L platelet &gt; 100 x 10^9/L Bilirubin &lt; 1.5 x ULN AST and/or ALT &lt; 2.5 x ULN absence liver metastasis AST and/or ALT &lt; 5 x ULN presence liver metastasis Serum creatinine &lt; 1.5 x ULN Creatinine clearance ( estimate accord CockcroftGault formula ) ≥ 50 ml/min Patients may prior therapy provide follow condition meet : Chemotherapy , radiation therapy , hormonal therapy immunotherapy : washout period 28 day Corticosteroid therapy wash period 14 day Surgery : washout period 14 day Patients must give write informed consent participate study Previous sign severe toxicity platinum related Patients must receive investigational agent study New York Heart Association class III IV cardiac disease Unstable angina Patients myocardial infarction within last six ( 6 ) month Patient significant peripheral vascular disease Clinical sign CNS involvement Patients active uncontrolled systemic disease/infections serious illness medical condition , incompatible protocol Known hypersensitivity/allergic reaction human albumin preparation excipients Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol Pregnancy lactation . Patients male female reproductive potential ( i.e . menopausal le 1year surgically sterilize ) must practice effective contraceptive measure throughout study . Women childbearing potential must provide negative pregnancy test ( serum urine ) within 14 day prior registration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>NGR-hTNF</keyword>
	<keyword>cisplatin</keyword>
	<keyword>solid tumor</keyword>
</DOC>